Trial
NCT02588261
A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Astellas Pharma Global Development, Inc.
Collaborators
—
Condition
Non-small Cell Lung Cancer (NSCLC)
Intervention
naquotinib mesilate
Why stopped
Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-12-10